Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Nov 11, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 08, 2022

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

Nov 07, 2022

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

Nov 02, 2022

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

Nov 01, 2022

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

Oct 12, 2022

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

Oct 07, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 09, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 06, 2022

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

Aug 16, 2022

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 39

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact